Drug of choice for typhoid
Reading File
Searching the Web
drug of choice typhoid fever 2024 2025 guidelines treatment
Finding Sources
Searching PubMed
typhoid fever treatment azithromycin ceftriaxone
Reading File
Reading File
Here is a thorough, up-to-date breakdown:
Drug of Choice for Typhoid Fever
Treatment selection depends on disease severity and local antibiotic resistance patterns, particularly whether the strain is fully sensitive, multidrug-resistant (MDR), or extensively drug-resistant (XDR).
By Susceptibility Pattern
| Susceptibility | First-Line (Optimal) | Dose | Duration | Alternatives |
|---|---|---|---|---|
| Fully sensitive | Fluoroquinolone (ciprofloxacin/ofloxacin) | 15 mg/kg/day | 5-7 days | Chloramphenicol, amoxicillin, TMP-SMX |
| Multidrug-resistant (MDR) | Fluoroquinolone OR cefixime | 15-20 mg/kg/day | 5-14 days | Azithromycin, cefixime |
| Quinolone-resistant | Azithromycin OR ceftriaxone | 8-10 mg/kg / 75 mg/kg | 7 / 10-14 days | Cefixime |
| XDR (Pakistan/Iraq) | Azithromycin (uncomplicated) / Meropenem (severe) | 1g then 500mg OD / 20 mg/kg TID | 7-14 days / per response | - |
Source: Park's Textbook of Preventive and Social Medicine; CDC Yellow Book 2024
Summary by Clinical Scenario
Uncomplicated typhoid (outpatient)
- Azithromycin is now the preferred empiric choice in most regions (especially where fluoroquinolone resistance is high, e.g., South Asia)
- Dosing: 1 g loading dose on day 1, then 500 mg once daily for 7 days
- Fluoroquinolones remain first-line only where susceptibility is confirmed
Severe/complicated typhoid (inpatient)
- Ceftriaxone IV is the standard of care
- In XDR regions (Pakistan, Iraq): meropenem (carbapenem) is preferred
- Add dexamethasone (high-dose) for shock, meningitis, or severe encephalopathy - this significantly reduces mortality
Resistance considerations
- Chloramphenicol, ampicillin, co-trimoxazole: once classic first-line drugs, now largely unreliable due to widespread resistance - only use if local susceptibility data confirm sensitivity
- Fluoroquinolones: >90% of US typhoid cases are fluoroquinolone-non-susceptible, mostly acquired in South Asia (CDC Yellow Book 2024)
- XDR typhoid: defined as resistance to all first-line, fluoroquinolones, AND third-generation cephalosporins - emerged from Pakistan ~2016 onward; carbapenems required
Carrier state treatment
- Ampicillin or amoxicillin (4-6 g/day) + probenecid for 6 weeks
- Cholecystectomy + ampicillin for biliary carriers (up to 80% cure rate)
- Chloramphenicol is ineffective for clearing carriers
Quick Memory Aid
| Scenario | Drug |
|---|---|
| Uncomplicated, empiric (most regions) | Azithromycin |
| Complicated / severe | Ceftriaxone IV |
| XDR (Pakistan/Iraq), uncomplicated | Azithromycin |
| XDR, complicated | Meropenem |
| Fluoroquinolone-sensitive (confirmed) | Ciprofloxacin / Ofloxacin |
| Severe with shock/meningitis | Add dexamethasone |
Key recent evidence: A 2024 systematic review (PMID: 39623850) confirmed the clinical efficacy of oral azithromycin vs. other antimicrobials for typhoid across all age groups.
Sources: Park's Preventive Medicine; Tintinalli's Emergency Medicine; Jawetz Microbiology; CDC Yellow Book 2024; MSF Medical Guidelines 2024
This is a shared conversation. Sign in to Orris to start your own chat.